Briacell Therapeutics Corp（BCTX）财务数据BCTXBriacell Therapeutics Corp

Evaluating the bottom line, Briacell Therapeutics Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -212.23%, provide a clear picture of how effectively BCTX converts its operational activities into shareholder value.

In the context of the broader market, BCTX competes directly with industry leaders such as ELUT and ZYBT. With a market capitalization of $34.48M, it holds a significant position in the sector. When comparing efficiency, BCTX's gross margin of N/A stands against ELUT's 59.62% and ZYBT's 20.51%. Such benchmarking helps identify whether Briacell Therapeutics Corp is trading at a premium or discount relative to its financial performance.

Briacell Therapeutics has reported no revenue for most quarters in 2025 and 2026, with a total revenue of only 225,340 USD in Q4 2025. The company has consistently posted significant net income losses, with the latest being -12,320,370 USD for Q4 2026. The gross profit remains negative, indicating ongoing operational challenges.